|
||
Hidralazina Clorhidrato Biosano Dosage |
||
Applies to the following strength(s): 25 mg; 50 mg; 10 mg; 100 mg; 20 mg/mL
The information at Drugs.com is not a substitute for medical advice. Always consult your doctor or pharmacist.
Initial dose: 10 mg orally 4 times a day for the first 2 to 4 days. Increase to 25 mg orally 4 times a day for the balance of the first week.
For the second and subsequent weeks, increase dosage to 50 mg orally 4 times a day.
Maintenance dose: Adjust dosage to the lowest effective levels.
Usual dose: 20 to 40 mg IV or IM, repeated as necessary. Certain patients (especially those with marked renal damage) may require a lower dose.
Initial dose: 10 mg orally 4 times a day
Maintenance dose: Doses up to 800 mg three times daily have been effective in reducing afterload in the treatment of congestive heart failure
CrCl < 10 mL/min: The dosing interval should be increased to every 8 to 16 hours in fast acetylators and every 12 to 24 hours in slow acetylators.
CrCl 10-50 mL/min: The dosing interval should be increased to every 8 hours.
Because Hidralazina Clorhidrato Biosano is primarily metabolized by the liver, it is recommended that dose increments be made cautiously (frequent blood pressure checks and monitoring for side effects) in patients with liver disease.
In a few resistant patients, up to 300 mg of Hidralazina Clorhidrato Biosano daily may be required for a significant antihypertensive effect. In such cases, a lower dosage of Hidralazina Clorhidrato Biosano combined with a thiazide and/or reserpine or a beta blocker may be considered. However, when combining therapy, individual titration is essential to ensure the lowest possible therapeutic dose of each drug.
Up to 20% of patients who receive 400 mg/day or more develop a systemic lupus erythematosus syndrome. Some experts recommended checking the acetylator status of the patient before giving higher doses. Fast acetylators can handle dosage increases more safely. Close monitoring for signs and symptoms of Hidralazina Clorhidrato Biosano-induced lupus has been strongly recommended.
No supplemental dose is necessary with hemo- or peritoneal dialysis.
Blood pressure of patients receiving IV or IM Hidralazina Clorhidrato Biosano may fall a few minutes after injection, with the average maximum decrease occurring in 10 to 80 minutes. Most patients can be transferred to oral Hidralazina Clorhidrato Biosano within 24 to 48 hours.
Before taking Hidralazina Clorhidrato Biosano, tell your doctor if you are taking any of the following medicines:
diazoxide (Hyperstat, Proglycem); or
an MAO inhibitor such as isocarboxazid (Marplan), phenelzine (Nardil), rasagiline (Azilect), selegiline (Eldepryl, Emsam), or tranylcypromine (Parnate).
This list is not complete and there may be other drugs that can interact with Hidralazina Clorhidrato Biosano. Tell your doctor about all your prescription and over-the-counter medications, vitamins, minerals, herbal products, and drugs prescribed by other doctors. Do not start a new medication without telling your doctor.
Alfuzosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Monitor therapy
Amifostine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Amifostine. Management: When amifostine is used at chemotherapy doses, blood pressure lowering medications should be withheld for 24 hours prior to amifostine administration. If blood pressure lowering therapy cannot be withheld, amifostine should not be administered. Consider therapy modification
Amphetamines: May diminish the antihypertensive effect of Antihypertensive Agents. Monitor therapy
Antipsychotic Agents (Second Generation [Atypical]): Blood Pressure Lowering Agents may enhance the hypotensive effect of Antipsychotic Agents (Second Generation [Atypical]). Monitor therapy
Barbiturates: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Monitor therapy
Benperidol: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Monitor therapy
Brigatinib: May diminish the antihypertensive effect of Antihypertensive Agents. Brigatinib may enhance the bradycardic effect of Antihypertensive Agents. Monitor therapy
Brimonidine (Topical): May enhance the hypotensive effect of Blood Pressure Lowering Agents. Monitor therapy
Bromperidol: May diminish the hypotensive effect of Blood Pressure Lowering Agents. Blood Pressure Lowering Agents may enhance the hypotensive effect of Bromperidol. Avoid combination
Dapoxetine: May enhance the orthostatic hypotensive effect of Hidralazina Clorhidrato Biosano. Monitor therapy
Dexmethylphenidate: May diminish the therapeutic effect of Antihypertensive Agents. Monitor therapy
Diazoxide: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Monitor therapy
DULoxetine: Blood Pressure Lowering Agents may enhance the hypotensive effect of DULoxetine. Monitor therapy
Herbs (Hypertensive Properties): May diminish the antihypertensive effect of Antihypertensive Agents. Monitor therapy
Herbs (Hypotensive Properties): May enhance the hypotensive effect of Blood Pressure Lowering Agents. Monitor therapy
Hypotension-Associated Agents: Blood Pressure Lowering Agents may enhance the hypotensive effect of Hypotension-Associated Agents. Monitor therapy
Levodopa-Containing Products: Blood Pressure Lowering Agents may enhance the hypotensive effect of Levodopa-Containing Products. Monitor therapy
Lormetazepam: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Monitor therapy
Methylphenidate: May diminish the antihypertensive effect of Antihypertensive Agents. Monitor therapy
Molsidomine: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Monitor therapy
Naftopidil: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Monitor therapy
Nicergoline: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Monitor therapy
Nicorandil: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Monitor therapy
Nitroprusside: Blood Pressure Lowering Agents may enhance the hypotensive effect of Nitroprusside. Monitor therapy
Nonsteroidal Anti-Inflammatory Agents: May diminish the antihypertensive effect of Hidralazina Clorhidrato Biosano. Monitor therapy
Obinutuzumab: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Management: Consider temporarily withholding blood pressure lowering medications beginning 12 hours prior to obinutuzumab infusion and continuing until 1 hour after the end of the infusion. Consider therapy modification
Pentoxifylline: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Monitor therapy
Pholcodine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Pholcodine. Monitor therapy
Phosphodiesterase 5 Inhibitors: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Monitor therapy
Prostacyclin Analogues: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Monitor therapy
Quinagolide: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Monitor therapy
Yohimbine: May diminish the antihypertensive effect of Antihypertensive Agents. Monitor therapy
There are no reviews yet. Be the first to write one! |
Information checked by Dr. Sachin Kumar, MD Pharmacology
|